Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | SCD | O00767 | 1/20 | 0.47 |
| ▸ | CBFB | Q13951 | 1/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 6/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM4B | O94953 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | GPR39 | O43194 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6067871 | 0.80 | KDM4E (0.54) | CBFBERN1KDM4AKDM5CCYP2A6 | |
| Hydrochloric Acid SCHEMBL6068087 | 0.78 | KDM4E (0.52) | CBFBERN1KDM4AKDM5CCYP2A6 | |
| SCHEMBL8229590 | 0.77 | PTGS2 (0.64) | PTGS2PTGS1SCDCBFBTGFBR1 | |
| SCHEMBL309425 | 0.77 | EGFR (0.49) | PTGS2 | |
| SCHEMBL23525598 | 0.76 | PKMYT1 (0.52) | KAT6AERN1CYP2A6 | |
| SCHEMBL8623707 | 0.76 | CCR1 (0.55) | PTGS2PTGS1SCDCBFBKDM4A | |
| SCHEMBL30610279 | 0.76 | PKMYT1 (0.52) | KAT6AERN1CYP2A6 | |
| SCHEMBL309551 | 0.74 | LOX (0.49) | PTGS2PTGS1SCDERN1 | |
| SCHEMBL21390791 | 0.74 | EGFR (0.49) | KAT6AERN1KDM4AKDM5CCYP2A6 | |
| SCHEMBL309954 | 0.73 | PTGS2 (0.56) | PTGS2PTGS1ERN1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093253-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2250150-A1 | LEUKOTRIENE B4 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009109483-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | PTGS2 40/4885PTGS1 31/4885SCD 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.